Quest Diagnostics Approved to Use Electronic Drug Test Process for Federally-Mandated Workforce by U.S. Health and Human Services

Quest Diagnostics, the world's leading provider of diagnostic services, announced today that the U.S. Department of Health and Human Services (HHS) has authorized the company to perform drug testing using electronic Custody and Control Forms (eCCF) for federally-mandated, safety-sensitive workers.

With the approval, Quest becomes the largest workplace drug testing provider certified to provide Federal eCCF, which can enhance efficiencies and improve the quality of the drug testing process, including collection and transport, by significantly reducing paper-based documentation.

The company is now certified to utilize eCCF for all urine workplace drug tests, following the successful completion by four of its workplace drug testing laboratories of the HHS National Laboratory Certification Program (NLCP) inspection and certification process, which involves demonstrating proficiency in several areas, including data security and confidentiality. The labs are located in Lenexa, KS; Tucker, GA; West Hills, CA; and West Norriton, PA. Quest Diagnostics plans to make federal eCCF broadly available to its clients in the fourth quarter.

Quest Diagnostics has provided eCCF to private, non-regulated employers for nearly a decade. The network is equipped with barcode scanners, electronic signature pads and other technologies enabling eCCF in 1,300 patient service centers and more than 1,000 preferred drug testing collection sites across the United States.

"Our eCCF certification positions us to comply with regulated drug testing requirements for workers in safety-sensitive roles, particularly workforces mandated by the U.S. Department of Transportation (DOT), to greatly improve the efficiency and quality of documentation for workplace drug testing," said Bob McCormick, Vice President, Quest Diagnostics Employer Solutions. "For years, we've successfully utilized eCCF to provide testing for millions of non-regulated specimens and we look forward to extending this capability to support federal drug-free workplace programs."